Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.42 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391032 | 0.80 | ERN1 (0.64) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL808500 | 0.80 | ERN1 (0.64) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9148679 | 0.78 | ERN1 (0.62) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL197337 | 0.78 | ERN1 (0.62) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31663413 | 0.78 | ERN1 (0.62) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL304032 | 0.77 | ERN1 (1.00) | ERN1MAPTCYP1A2L3MBTL1NPC1 | |
| SCHEMBL230035 | 0.77 | ERN1 (0.60) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7254708 | 0.77 | ERN1 (0.60) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11041721 | 0.77 | ERN1 (0.60) | ERN1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1664873 | 0.77 | ERN1 (0.60) | ERN1MAPTCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | claimed |
| EP-2222287-A2 | MULTITARGET COMPOUNDS ACTIVE AT A PPAR AND CANNABINOID RECEPTOR | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009080821-A2 | RECEPTOR TARGETING LIGANDS | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | claimed |
| EP-0374510-B1 | Products for the treatment of endotoxic shock in a mammal | AMERICAN CYANAMID CO (US) | 1997-01-15 | — | — | EP | claimed |
| US-5411983-A | Certain hyrdoxy-phosphinyl-oxy-phenylmethyl-imidazolium hydroxide inner salts as PAF antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-05-02 | — | — | US | claimed |
| US-5215975-A | Certain hydroxy-phosphinyl-oxy-phenyl methyl-thiazolium hydroxide inner salts as PAF antagonists | AMERICAN CYANAMID COMPANY (US) | 1993-06-01 | — | — | US | claimed |
| US-5124147-A | Mixture of antagonist to platelet activating factor and antibody | AMERICAN CYANAMID COMPANY (US) | 1992-06-23 | — | — | US | claimed |
| EP-0374510-A1 | Products for the treatment of endotoxic shock in a mammal | AMERICAN CYANAMID COMPANY (US) | 1990-06-27 | — | — | EP | claimed |
| EP-0336142-A2 | Novel antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1989-10-11 | — | — | EP | claimed |
| WO-2022049686-A1 | METHOD FOR MANUFACTURING COLOR FILTER PIGMENT | DIC株式会社 | 2022-03-10 | — | — | WO | disclosed |
| US-11118272-B2 | Heterocyclic corrosion inhibitor compounds and uses thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2021-09-14 | — | — | US | disclosed |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | KING ABDULAZIZ UNIVERSITY (SA) | 2021-03-30 | — | — | US | disclosed |
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-03 | — | — | US | disclosed |
| US-5215975-A | Certain hydroxy-phosphinyl-oxy-phenyl methyl-thiazolium hydroxide inner salts as PAF antagonists | AMERICAN CYANAMID COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0336142-A3 | NOVEL ANTAGONISTS OF PLATELET ACTIVATING FACTOR | AMERICAN CYANAMID COMPANY (US) | 1991-04-24 | — | — | EP | disclosed |
| EP-0374510-A1 | Products for the treatment of endotoxic shock in a mammal | AMERICAN CYANAMID COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| EP-0336142-A2 | Novel antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
| EP-0336142-A2 | Novel antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
| US-4369189-A | INSECTICIDES, MITICIDES NEMATOCIDES | UNION CARBIDE CORPORATION (US) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368204-A1 | COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN | MAVS, CUL1, CUL3 | ERN1 129/4885MAPT 1093/4885CYP1A2 1431/4885 |
| US-10821096-B1 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | MAVS, CUL1, CUL3 | ERN1 129/4885MAPT 1093/4885CYP1A2 1431/4885 |
| US-10959987-B2 | Imidazole-based compounds as hepatitis C virus inhibitors | HAVCR2, MAVS, ZC3HAV1 | ERN1 915/4885MAPT 269/4885CYP1A2 117/4885 |
| US-11118272-B2 | Heterocyclic corrosion inhibitor compounds and uses thereof | AOC1, AOC2, MYB | ERN1 536/4885MAPT 4445/4885CYP1A2 2772/4885 |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | PPARA, PPARG, PPARD | ERN1 4191/4885MAPT 3469/4885CYP1A2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.